 Sutro Biopharma Inc NASDAQ: STRO has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA Germany OTC: MKGAF. The payment is related to a patient enrollment achievement in the Phase 1 dose-escalation and expansion study of M1231 in adult patients with metastatic solid tumors. 